VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

robot
Abstract generation in progress

Faruqi & Faruqi, LLP is reminding investors of Vistagen Therapeutics (VTGN) about the March 16, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Vistagen made misleading statements regarding the likelihood of success for its fasedienol treatment after the PALISADE-3 clinical trial failed to meet its primary efficacy endpoint, causing a significant drop in stock price. Investors who purchased VTGN securities between April 1, 2024, and December 16, 2025, are encouraged to contact the law firm to discuss their legal options.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin